In a 72-h MTT assay, tanshinone IIA had a reported IC50 of 5.32 µM in A549 cells and >40 µM in NQO1-negative H596 cells. These are model-specific metabolic-viability endpoints, not treatment doses or universal potency values. [2]
In human GBM59 spheroids, tanshinone IIA (3.77 µM) combined with Paxalisib (0.46 µM) enhanced growth inhibition relative to Paxalisib alone over nine days. The high-dose combination reduced volume below its starting value. This combination result does not establish a single-agent clinical effect. [1]
Cellular PIP3 response in Dictyostelium
Cell-based study · Dictyostelium discoideum Ax3 cells expressing PHCrac-GFP [1]
T2A suppressed cAMP-stimulated PHCrac-GFP membrane recruitment, a cellular readout of PIP3 production. The reported acute IC50 was 1.57 µM. Solvent and LY294002 controls support assay interpretation; this is not a purified PI3K enzyme assay or a direct binding measurement.
Literature-Reported Treatment Conditions
- Treatment concentration
- T2A 0–25 µM (acute concentration response); 25 µM (4-h comparison)
- Exposure duration
- 15 min for acute concentration response; 4 h for prolonged comparison
- Method
- PHCrac-GFP membrane translocation after cAMP stimulation; comparison with solvent and LY294002
- Vehicle
- 0.2% DMSO
- Co-treatment
- LY294002 comparator; combination responses not adopted
- Reported limits
- No purified-enzyme potency or PI3K isoform selectivity established in this assay.
Methods and source locations
Compound reported in the paper: Tanshinone IIA; Compound label in the paper: T2A
Experimental findings for the reported parent compound and tested material; no validation of the current AdooQ lot or human efficacy.
Results Sec4; Fig. 2B–F; Methods Sec13, Sec16; SI captions S1–S2
Inhibition of stimulated PIP3-associated membrane recruitment: PHCrac-GFP fluorescence assay; 15-min treatment; mean ± SEM; Fig. 2 caption reports at least N = 6, three independently stimulated cells per experiment (technical observations are not additional biological replicates). — Results Sec4; Fig. 2E–F; Methods Sec16
Tanshinone IIA with Paxalisib in human GBM59 spheroids
Cell-based study · Patient-derived human GBM59 cells grown as 3D spheroids [1]
At T2A 3.77 µM and Paxalisib 0.46 µM, the combination reduced spheroid growth more than Paxalisib alone. The high-dose combination produced regression relative to starting volume at day 9. Single-agent, combination and solvent groups were compared in the same design. Not an animal experiment or clinical response.
Literature-Reported Treatment Conditions
- Treatment concentration
- T2A 3.77 µM; Paxalisib 0.46 µM
- Exposure duration
- 9 days; size assessed before treatment and on days 3, 6 and 9
- Method
- Microscopy with ImageJ; spherical volume estimated from spheroid size
- Vehicle
- Solvent-only control; spheroid solvent identity/final percentage not specified in this method
- Co-treatment
- Paxalisib 0.46 µM; both single-agent comparators included
- Reported limits
- No exact volume estimated from plotted curves; no Bliss synergy claim adopted; no GL261 timing assumption. Seeding statement and monolayer doses are not adopted as spheroid conditions.
Methods and source locations
Compound reported in the paper: Tanshinone IIA; Compound label in the paper: T2A
Experimental findings for the reported parent compound and tested material; no validation of the current AdooQ lot or human efficacy.
Results Sec9; Fig. 7A–C (high-dose GBM59 comparison); Methods Sec13, Sec19–Sec20
Spheroid volume change at day 9: Fig. 7A–C image and caption; mean ± SEM, 3 biological repeats, 3 technical repeats each; two-tailed Mann–Whitney test. Exact volumes not transcribed. — Results Sec9; Fig. 7A–C; Methods Sec19–Sec20
NQO1-dependent cellular sensitivity
Cell-based study · Human NSCLC A549 and NCI-H596 cells; NQO1 perturbation controls [2]
In a 72-h MTT assay A549 cells were more sensitive than NQO1-negative H596 cells. Dicoumarol and NQO1 siRNA reduced A549 sensitivity; matched NQO1-expression versus vector controls supported NQO1 dependence. p53 inhibition or knockdown had little effect in this design. These model-dependent results do not establish a universal cytotoxic concentration.
Literature-Reported Treatment Conditions
- Treatment concentration
- TSA 0.4–40 µM for parental-cell dose response; matched-cell dose response extends to 80 µM in Fig. 1E
- Exposure duration
- 72 h
- Method
- MTT endpoint; untreated control, pharmacological and gene-perturbation comparisons
- Vehicle
- Treatment vehicle composition not specified in Cytotoxicity assay method
- Co-treatment
- DIC 10 µM pretreatment for 30 min; NAC and p53 inhibitor/siRNA controls are distinct from single-agent IC50 assays
- Reported limits
- Treatment vehicle not established; MTT reports metabolic viability, not a direct cell-count endpoint; no uncertainty supplied for fitted IC50 values.
Methods and source locations
Compound reported in the paper: Tanshinone IIA; Compound label in the paper: TSA
Experimental findings for the reported parent compound and tested material; no validation of the current AdooQ lot or human efficacy.
Results s2a; Fig. 1A–F; Methods s4b–s4e, s4k, s4p
A549 metabolic viability: MTT; results s2a; Fig. 1 data mean ± SE of three independent experiments (not an IC50 error interval). — Results s2a; Fig. 1B; Methods s4e
NQO1-negative H596 metabolic viability: MTT; resistant comparator tested alongside A549. Operator retained as reported. — Results s2a; Fig. 1B; Methods s4e